{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:15:28Z","timestamp":1783376128291,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"28","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,7,28]]},"DOI":"10.1038\/s41388-026-03855-0","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:04:52Z","timestamp":1781247892000},"page":"2851-2864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CPSF2-mediated 3\u2019 UTR truncation of MTERF3 drives mitochondrial dysfunction and osteosarcoma progression"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-3519","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"3855_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23:192.","journal-title":"Mol Cancer"},{"key":"3855_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, et al. Osteosarcoma. Nat Rev Dis Primers. 2022;8:77.","journal-title":"Nat Rev Dis Primers"},{"key":"3855_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41576-019-0145-z","volume":"20","author":"AJ Gruber","year":"2019","unstructured":"Gruber AJ, Zavolan M. Alternative cleavage and polyadenylation in health and disease. Nat Rev Genet. 2019;20:599\u2013614.","journal-title":"Nat Rev Genet"},{"key":"3855_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.gendis.2021.09.005","volume":"10","author":"S Guo","year":"2023","unstructured":"Guo S, Lin S. mRNA alternative polyadenylation (APA) in regulation of gene expression and diseases. Genes Dis. 2023;10:165\u201374.","journal-title":"Genes Dis"},{"key":"3855_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104599","volume":"206","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Huang Z, Lu W, Liu Z. Alternative polyadenylation in cancer: Molecular mechanisms and clinical application. Crit Rev Oncol Hematol. 2024;206:104599.","journal-title":"Crit Rev Oncol Hematol."},{"key":"3855_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1080\/15476286.2023.2275109","volume":"20","author":"L Gallicchio","year":"2023","unstructured":"Gallicchio L, Olivares GH, Berry CW, Fuller MT. Regulation and function of alternative polyadenylation in development and differentiation. RNA Biol. 2023;20:908\u201325.","journal-title":"RNA Biol"},{"key":"3855_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2007.05.046","volume":"130","author":"CB Park","year":"2007","unstructured":"Park CB, Asin-Cayuela J, Camara Y, Shi Y, Pellegrini M, Gaspari M, et al. MTERF3 is a negative regulator of mammalian mtDNA transcription. Cell. 2007;130:273\u201385.","journal-title":"Cell"},{"key":"3855_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/tcr.2019.12.65","volume":"9","author":"WS Wang","year":"2020","unstructured":"Wang WS, Zi JJ, Sun MT, Mei W, Li SF, Yang N, et al. Expression of MTERF3 gene in breast carcinoma and the relationship with clinicopathological characteristics. Transl Cancer Res. 2020;9:173\u201386.","journal-title":"Transl Cancer Res"},{"key":"3855_CR9","first-page":"1909","volume":"12","author":"J Zi","year":"2019","unstructured":"Zi J, Wang W, Sun M, Mei W, Li S, Li B, et al. A high expression of MTERF3 correlates with tumor progression and predicts poor outcomes in patients with brain glioma. Int J Clin Exp Pathol. 2019;12:1909\u201320.","journal-title":"Int J Clin Exp Pathol"},{"key":"3855_CR10","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.7150\/ijbs.36916","volume":"15","author":"X Liu","year":"2019","unstructured":"Liu X, Cao X, Liu C, Cao Y, Zhao Q, Tan X, et al. MTERFD1 promotes cell growth and irradiation resistance in colorectal cancer by upregulating interleukin-6 and interleukin-11. Int J Biol Sci. 2019;15:2750\u201362.","journal-title":"Int J Biol Sci"},{"key":"3855_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1089\/gtmb.2023.0108","volume":"27","author":"MT Sun","year":"2023","unstructured":"Sun MT, Zhao HY, Ruan HJ, Yu LH, Guan ML, Fan JJ, et al. Prognostic Role of Mitochondrial Transcription Termination Factor 3 in Thyroid Carcinoma. Genet Test Mol Biomarkers. 2023;27:362\u20139.","journal-title":"Genet Test Mol Biomarkers"},{"key":"3855_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216925","volume":"593","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu D, Guo D, Lin W, Lu W, Hu L, et al. CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression. Cancer Lett. 2024;593:216925.","journal-title":"Cancer Lett"},{"key":"3855_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.molcel.2019.11.005","volume":"77","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Sun Y, Shi Y, Walz T, Tong L. Structural Insights into the Human Pre-mRNA 3\u2019-End Processing Machinery. Mol Cell. 2020;77:800\u20139.e6.","journal-title":"Mol Cell"},{"key":"3855_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41580-022-00507-5","volume":"23","author":"S Mitschka","year":"2022","unstructured":"Mitschka S, Mayr C. Context-specific regulation and function of mRNA alternative polyadenylation. Nat Rev Mol Cell Biol. 2022;23:779\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3855_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185\u201397.","journal-title":"Cancer Cell"},{"key":"3855_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s42003-023-05664-7","volume":"7","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zhao Y, Yu H, Wang T, Li J, Xu L, et al. Suppressing MTERF3 inhibits proliferation of human hepatocellular carcinoma via ROS-mediated p38 MAPK activation. Commun Biol. 2024;7:18.","journal-title":"Commun Biol"},{"key":"3855_CR17","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.230221","volume":"13","author":"S Thore","year":"2023","unstructured":"Thore S, Raoelijaona F, Talenton V, Fribourg S, Mackereth CD. Molecular details of the CPSF73-CPSF100 C-terminal heterodimer and interaction with Symplekin. Open Biol. 2023;13:230221.","journal-title":"Open Biol"},{"key":"3855_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57402-6","volume":"14","author":"X Li","year":"2024","unstructured":"Li X, Che Y, Wang X, Zhu Y. A pan-cancer analysis of the core pre-mRNA 3\u2019 end processing factors, and their association with prognosis, tumor microenvironment, and potential targets. Sci Rep. 2024;14:17428.","journal-title":"Sci Rep"},{"key":"3855_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1089\/thy.2015.0079","volume":"25","author":"TY Sung","year":"2015","unstructured":"Sung TY, Kim M, Kim TY, Kim WG, Park Y, Song DE, et al. Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma. Thyroid. 2015;25:1020\u20135.","journal-title":"Thyroid"},{"key":"3855_CR20","doi-asserted-by":"publisher","first-page":"53.","DOI":"10.3390\/biomedicines11010053","volume":"11","author":"I Ivkovic","year":"2022","unstructured":"Ivkovic I, Limani Z, Jakovcevic A, Gajovic S, Seiwerth S, Danic Hadzibegovic A, et al. Prognostic Significance of BRAF V600E Mutation and CPSF2 Protein Expression in Papillary Thyroid Cancer. Biomedicines. 2022;11:53.","journal-title":"Biomedicines"},{"key":"3855_CR21","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-22-0909","volume":"82","author":"Q Guo","year":"2022","unstructured":"Guo Q, Wang H, Duan J, Luo W, Zhao R, Shen Y, et al. An Alternatively Spliced p62 Isoform Confers Resistance to Chemotherapy in Breast Cancer. Cancer Res. 2022;82:4001\u201315.","journal-title":"Cancer Res"},{"key":"3855_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100933","volume":"68","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xie Y, Li Q, Zhang Z, Chen J, Zhang K, et al. CPSF6-mediated XBP1 3\u2019UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2023;68:100933.","journal-title":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"3855_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.829212","volume":"12","author":"R Guo","year":"2022","unstructured":"Guo R, Liu T, Shasaltaneh MD, Wang X, Imani S, Wen Q. Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer Therapy. Front Oncol. 2022;12:829212.","journal-title":"Front Oncol"},{"key":"3855_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176770","volume":"978","author":"W Wang","year":"2024","unstructured":"Wang W, Xue Y, Li D, Shao C, Wu K, Sun N, et al. Forskolin is an effective therapeutic small molecule for the treatment of hypertrophic cardiomyopathy through ADCY6\/cAMP\/PKA pathway. Eur J Pharmacol. 2024;978:176770.","journal-title":"Eur J Pharmacol"},{"key":"3855_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.molmet.2019.11.008","volume":"31","author":"L Jia","year":"2020","unstructured":"Jia L, Jiang Y, Li X, Chen Z. Purbeta promotes hepatic glucose production by increasing Adcy6 transcription. Mol Metab. 2020;31:85\u201397.","journal-title":"Mol Metab"},{"key":"3855_CR26","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/kjm2.12725","volume":"39","author":"S Yang","year":"2023","unstructured":"Yang S, Guo LJ, Liang Y, He ZM, Luo J, Mu YD. ADCY6 is a potential prognostic biomarker and suppresses OTSCC progression via Hippo signaling pathway. Kaohsiung J Med Sci. 2023;39:978\u201388.","journal-title":"Kaohsiung J Med Sci"},{"key":"3855_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957511","volume":"12","author":"H Wu","year":"2022","unstructured":"Wu H, Qiu J, Wu Z, He T, Zhou C, Lv Q. MiR-27a-3p binds to TET1 mediated DNA demethylation of ADCY6 regulates breast cancer progression via epithelial-mesenchymal transition. Front Oncol. 2022;12:957511.","journal-title":"Front Oncol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03855-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:02:45Z","timestamp":1783375365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03855-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":27,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026,7,28]]}},"alternative-id":["3855"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03855-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Shantou University Medical College Cancer Hospital (Approval number: KY2023-720-01). Written informed consent was obtained from all participants. Animal studies were conducted in accordance with the approved protocols and guidelines set forth by the Institutional Animal Care and Use Committee of the Chinese Academy of Medical Sciences. The animal experiments received approval from the Animal Ethics Committee of Shantou University Medical College (SUMCXM2024-152).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}